Rankings
▼
Calendar
TEVA Q4 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$37B
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.7B
+11.4% YoY
Gross Profit
$2.7B
56.4% margin
Operating Income
$300M
6.4% margin
Net Income
$480M
10.2% margin
EPS (Diluted)
$0.41
QoQ Revenue Growth
+5.2%
Cash Flow
Operating Cash Flow
$1.2B
Free Cash Flow
$1.0B
Stock-Based Comp.
$51M
Balance Sheet
Total Assets
$40.7B
Total Liabilities
$32.8B
Stockholders' Equity
$7.9B
Cash & Equivalents
$3.6B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.7B
$4.2B
+11.4%
Gross Profit
$2.7B
$2.1B
+25.3%
Operating Income
$300M
-$29M
+1134.5%
Net Income
$480M
-$217M
+321.2%
Revenue Segments
Product
$3.7B
78%
License
$550M
12%
Distribution Service
$384M
8%
Product and Service, Other
$109M
2%
Geographic Segments
United States Segment
$4.6B
71%
Europe Segment
$1.3B
21%
International Markets
$528M
8%
← FY 2025
All Quarters